To ascertain whether the reversal of drug resistance by SQFZ in breast cancer cells correlated with activation of the PI3K signalling pathway, MDA-MB-231/DDP+M2 cells were treated with a PI3K-specific inhibitor (LY294002) or an activator (IGF-1). This evidence concerns the gene IGF1 and breast carcinoma.